Status: Recruiting
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
Participants needed: 106
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Mission TherapeuticsUpdated: Aug 19, 2026Locations: 18
Eligibility criteria
Male and female participants aged ≥ 40 to ≤ 75 years. [+12]
A clinically significant history of gastrointestinal disorders or any significan... [+113]